Equities

Sutro Biopharma Inc

Sutro Biopharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.38
  • Today's Change0.22 / 5.29%
  • Shares traded518.75k
  • 1 Year change+80.25%
  • Beta1.2302
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments376334198
Total Receivables, Net367.1212
Total Inventory------
Prepaid expenses9.85128.12
Other current assets, total------
Total current assets422353219
Property, plant & equipment, net455152
Goodwill, net------
Intangibles, net------
Long term investments--069
Note receivable - long term------
Other long term assets3.571.861.66
Total assets471407341
LIABILITIES
Accounts payable9.444.8011
Accrued expenses603212
Notes payable/short-term debt000
Current portion long-term debt/capital leases4.06139.38
Other current liabilities, total21178.58
Total current liabilities946742
Total long term debt03.7716
Total debt4.061625
Deferred income tax------
Minority interest------
Other liabilities, total22712031
Total liabilities32119089
SHAREHOLDERS EQUITY
Common stock0.060.060.05
Additional paid-in capital709670586
Retained earnings (accumulated deficit)(559)(453)(333)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.02(0.62)(0.31)
Total equity150217253
Total liabilities & shareholders' equity471407341
Total common shares outstanding615746
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.